GlassScriptPhysician profile
Elizabeth Lanham
NPI 1760713390
$1,826.08
in general payments reported to CMS, 2019-2025
14 companies · $794 in 2025
The $794 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.23 · 2022: $51.73 · 2023: $276 · 2024: $646 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $977.34 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $216.90 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.84 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $130.51 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Alkermes, INC. | $53.31 | 2022-2025 | Vivitrol |
| Pfizer INC. | $49.80 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $42.31 | 2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $29.15 | 2021-2024 | Zepbound, Mounjaro |
| Braeburn INC. | $26.05 | 2023 | Brixadi |
| Novo Nordisk INC | $25.64 | 2022-2024 | Wegovy |
| Phadia US INC. | $23.68 | 2025 | Immunocap |
| Philips North America LLC | $22.53 | 2024 | (Ck7) Extended Holter |
| Currax Pharmaceuticals LLC | $15.09 | 2023 | Contrave |
| Astellas Pharma US INC | $13.93 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lanham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.